At this time, a generic version of Gilenya (fingolimod) is not available. The first patent for this medication is set to expire in 2014, which is the earliest predictable date that a generic version could become available. It is important to note that fingolimod is the "generic name" for Gilenya, not a generic version of it.
Gilenya™ (fingolimod) is a prescription medication approved to treat multiple sclerosis (MS). The drug is classified as a "sphingosine 1-phosphate receptor modulator" and is taken by mouth (in contrast to most MS medications, which are given by injection).
Gilenya is made by Novartis Pharmaceuticals Corporation. This medication is protected from generic competition by a patent that has not yet expired.
The first patent for Gilenya currently expires in February 2014. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to extend or shorten this exclusivity period. This could include such things as lawsuits or other patents for specific Gilenya uses. Once the drug goes off-patent, there may be several companies that manufacture a generic Gilenya medication.
No -- fingolimod is the active ingredient in Gilenya, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent, and another company besides the original manufacturer must make the product.